Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.54 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.53 |
| ▸ | AAK1 | Q2M2I8 | 6/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.50 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.49 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1753916 | 1.00 | ABCB1 (0.54) | ABCB1ABCC1AAK1HDAC2HDAC1 | |
| Ammonia Solution, Strong SCHEMBL21835798 | 0.99 | ABCB1 (0.53) | ABCB1ABCC1AAK1HDAC2HDAC1 | |
| SCHEMBL3786645 | 0.90 | AAK1 (0.53) | ABCB1ABCC1AAK1HDAC2HDAC1 | |
| SCHEMBL3790831 | 0.89 | AAK1 (0.47) | ABCB1ABCC1AAK1HDAC2HDAC1 | |
| SCHEMBL5868898 | 0.89 | HDAC2 (0.50) | ABCB1ABCC1AAK1HDAC2HDAC1 | |
| SCHEMBL24233399 | 0.89 | AAK1 (0.52) | ABCB1ABCC1AAK1HDAC2HDAC1 | |
| SCHEMBL3790650 | 0.89 | HDAC2 (0.65) | HDAC2HDAC1HDAC3 | |
| SCHEMBL5869075 | 0.89 | AAK1 (0.52) | ABCB1ABCC1AAK1CYP17A1MAP4K4 | |
| SCHEMBL197036 | 0.88 | CYP17A1 (0.54) | ABCB1ABCC1AAK1HDAC2HDAC1 | |
| SCHEMBL5868853 | 0.88 | AAK1 (0.51) | ABCB1ABCC1AAK1HDAC2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7151098-B2 | Glutamate receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2006-12-19 | — | — | US | disclosed |
| US-20060148791-A1 | Glutamate receptor antagonists | ADAM GEO | 2006-07-06 | — | — | US | disclosed |
| US-7018998-B2 | Glutamate receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2006-03-28 | — | — | US | disclosed |
| US-6960578-B2 | Glutamate receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2005-11-01 | — | — | US | disclosed |
| US-20050234048-A1 | Glutamate receptor antagonists | ADAM GEO | 2005-10-20 | — | — | US | disclosed |
| EP-1224175-B1 | BENZODIAZEPINE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2004-03-17 | — | — | EP | disclosed |
| US-20030092677-A1 | Glutamate receptor antagonists | ADAM GEO (DE) | 2003-05-15 | — | — | US | disclosed |
| US-6509328-B1 | Metabotropic glutamate receptor antagonists and accordingly are useful for the treatment of a range of neurological disorders, including psychosis, schizophrenia, Alzheimer's and others | HOFFMANN-LA ROCHE INC. | 2003-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092677-A1 | Glutamate receptor antagonists | GRM1, GRM3, GRM2 | ABCB1 1092/4885ABCC1 768/4885AAK1 1593/4885 |
| US-20050234048-A1 | Glutamate receptor antagonists | GRM3, GRM1, GRM2 | ABCB1 1124/4885ABCC1 1354/4885AAK1 2207/4885 |
| US-20060148791-A1 | Glutamate receptor antagonists | GRM3, GRM1, GRM2 | ABCB1 1124/4885ABCC1 1354/4885AAK1 2207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.